ClinicalTrials.gg
Not yet recruitingNCT07747766PARTS-IPV RCTUpdated Aug 5, 2026

Program for Alleviating Relationship Trauma and Stress for Intimate Partner Violence - Randomized Control Trial

An interventional study of Program For Alleviating Relationship Trauma and Stress through New Behaviors and DVIT Treatment As Usual (TAU) in Individuals Who Use Violence and Interpersonal Violence, sponsored by Cambridge Health Alliance. Not yet recruiting at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Cambridge Health Alliance · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This research study investigates the feasibility of a randomized control trial of a group-based treatment program for reducing stress, trauma, substance use, and use of violence among individuals who were court-mandated to attend a program after committing an act(s) of domestic violence. The study is in a 2-arm design with an intervention group and a control group.

Read the detailed description

We previously tested a pilot program called PARTS-NB (Program For Alleviating Relationship Trauma and Stress- New Behaviors), an adaptation of the original PARTS Program and a study registered under the name of PARTS IPV (NCT06765122). The pilot program included unique and specific elements for People who Use Violence (PUV) in intimate relationships. Preliminary results from the PARTS IPV pilot suggest that intervention-based feasibility was met, with a total of 13 individuals attending at least 1 group and 12/13 individuals attending at least 8/12 of the first 12 groups. Mean acceptability was 26 (SD =3.4) meeting the acceptability criteria for the intervention at week 12. Moreover, individuals in the pilot PARTS IPV had overall declines in their aggression scales, minor psychological aggression (CTS2) and trended towards lower values and less variance in severe psychological aggression (CTS2). Interestingly, we also observed reductions in the frequency of individuals having six or more drinks (Question 3, AuditC).

Given these results, this project is an important and timely study with high-quality pilot randomized control clinical trial design. The methodology aligns closely with the specific aims described in this application and uses several innovative features and some carefully implemented gold-standard measures to ensure a high likelihood of success and publication. This will be the first RCT testing an intensive model of IFS group therapy designed specifically for those who use violence within intimate partner relationships with concurrent intermittent individual meetings for ongoing evaluation and support.

Previous reviews of interventions suggest there is a gap in effective interventions to treat IPV for those with trauma backgrounds (Cheng et al., 2021; Travers et al. 2021). PARTS1, PARTS2 and PARTS for Substance Use Disorder (PARTS SUD) have all demonstrated enhanced emotion regulation and self-related processing (Comeau et al. 2024; Ally et al. 2025; Joss et al. 2026). The protocol's methodology follows previous intimate partner violence studies, incorporating verbal consent and partner inclusion, while employing rigorously implemented informed consent procedures and gold-standard measures to enhance the likelihood of success and publication. While CBT IPV interventions vary in length (e.g., Strength at Home (SAH) groups are 12-weeks, standard state programs such as the psychoeducation program in the State of Washington are 26 sessions), we will use a phased approach that will run a total of 20 weeks with 20 group sessions and 6-9 individual sessions.

Primary Aims The primary aim of this study is to conduct a NIH Stage III hybrid "real-world implementation" study assessing the feasibility and acceptability (Nathan, 2007; Onken et al., 2014) of an Internal Family Systems intensive group program (Program for Alleviating and Reducing Trauma and Stress - IPV) (PARTS-IPV Phase 2) versus domestic violence treatment intervention treatment as usual (DVIT-TAU) control group on individuals mandated for treatment. We have two primary aims for this pilot RCT protocol: feasibility and acceptability.

Feasibility is defined in two ways: intervention-based feasibility: in both arms, we expect 70% of participants completing at least 67% (e.g., 8/12) of the first 12 groups. For study-protocol feasibility we do not expect differences in the arms but expect each arm to obtain overall 67% or more of participants completing week-20 study assessments (H1.1).

Secondary Aims H2.1: A secondary aim is overall acceptability of the intervention as measured by the Client Satisfaction Questionnaire (CSQ-8) (Larsen et al., 1979) where for both arms, we expect a mean score of at least 20 out of a total of 32 (H2.1).

H2.2: Intervention satisfaction, as measured by a satisfaction question (would you recommend a friend) will obtain at least a mean of 7 out of 10 (H2.2) in week 20 for both arms.

H2.3: Another secondary aim of the study is to investigate the potential effects of the intervention on the Revised Conflict Tactics Scale (CTS2) (Straus et al., 1996; Chapman \& Gillespie, 2019) and Multidimensional Measure of Emotional Abuse- Restrictive Engulfment (MMEA-RE Subscale) (Murphy \& Hoover, 1999). We hypothesize a risk reduction in physical and psychological violence from self-reports in both arms IFS/DVIT-TAU arm (H2.3). In our pilot (N=12), baseline mean of the psychological aggression subscale was 0.51 (SD=0.17), indicating that some participants had very high aggression scores while others did not. In Week 12, the mean was 0.13 (SD=0.12), suggesting that everyone clustered near zero, with a reduction in variability and suggesting a potential for stabilization in risk. Risk reduction in this case is both improvement and stabilization (decreased or stable scores).

For this pilot RCT, we hypothesize a greater risk reduction (decreased/stable scores) of psychological aggression use in the IFS arm compared to DVIT-TAU as measured by the psychological aggression subscale in CTS2 and MMEA-RE Subscale (H2.3).

H2.4: Lastly, in the pilot, we observed declines in the Aggression Experience Sampler (AES) from baseline to week 12. Average baseline scores were 13.97 (SE=0.63) with weekly rates of decline of -0.06 (p-value=0.09), indicating decreases ranging from 0.01 to 0.13 points per week. Based on these pilot findings we hypothesize that the 20-week RCT intervention will produce a weekly decline of -0.04 in AES scores (H2.4).

Exploratory Aims Exploratory outcomes include effects on mechanisms of emotion regulation, decentering, self-critical rumination, and self-compassion.

We hypothesize a greater capacity for decentering (Experiences Questionnaire - Decentering subscale (EQ)), reductions in self-critical rumination, reactivity in interpersonal relationships (OAS2, IRI-SF), as well as an increase in emotion identification and regulation (PAQ-S, Difficulties in Emotion Regulation Scale (DERS)), transcendent experiences (NADA-Bliss subscale), and self-compassion (using Self-Compassion Scale Short Form (SCS-SF)) self report, in IFS PARTS compared to DVIT-TAU at week 12 and 20. Other exploratory aims of the study are to investigate the effects of the intervention on general mental health including posttraumatic stress disorder, depression, anxiety (Achtyes et al., 2015; Guinart et al., 2021), and substance use (Craving Scale, AUDIT-C).

02

Conditions studied

  • Individuals Who Use Violence
  • Interpersonal Violence

Keywords

  • Interpersonal Violence
  • Domestic Violence
  • Internal Family Systems (IFS)
  • Program For Alleviating Relationship Trauma and Stress (PARTS)
03

In context

Lead sponsor

Cambridge Health Alliance is the lead sponsor of 52 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be male-identifying or prefer to be in a male-identifying group;
  • Must be a resident of Washington state;
  • Must be court-referred to a treatment program for using violence with an intimate partner;
  • Have sufficient English fluency and literacy skills to understand the consent process, procedures and questionnaires and have the ability to provide written ;
  • Have access to the internet and an electronic device with adequate data capacity; to complete questionnaires online and attend online video conference groups;
  • Must be available and willing to attend at least 17 out of 20 scheduled online group sessions; and
  • Must be available and willing to complete the online computerized assessments, and phone interviews.

Exclusion criteria

Exclusion Criteria:

  • Insufficiently stable housing or internet connection to be able to join at least 17 group sessions;
  • Current participation in another experimental research study;
  • Expected medical hospitalization in the next six months from study enrollment period;
  • Current or expected physical incarceration (excluding house arrest or other forms of electronic monitoring) in the next six months from study enrollment period;
  • Inpatient hospitalization for mental health, substance use, suicide attempt or self-harm within past three months;
  • Inability to participate safely in the study intervention and without disrupting the group (in the opinion of principal investigator OR meeting any of the following criteria)
  • Past year history of a psychotic disorder or clinician confirmed active psychosis assessed by the Structured Clinical Interview for (SCID-5);
  • Bipolar I disorder history or current severe level of mania assessed by the Structured Clinical Interview for DSM-5 (SCID-5);
  • Acute suicidality with intent will be excluded from the study (Structured Clinical Interview for DSM-5 [SCID-5]);
  • High levels of Psychopathy as defined by self-report psychopathy checklist (SRP-4);
  • Self-injurious behavior in past three months will require clinical assessment prior to participation in the program;
  • Acute homicidality with plan and/or intent;
  • Inability to join a group without intoxication.
  • Prior experience or exposure with Internal Family Systems (e.g. IFS therapy, IFS groups or retreats, current IFS practice, etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    PARTS-NB Arm

    Participants (N=24 anticipated) randomly allocated to this arm with undergo an IFS-based intervention called PARTS-NB, which curriculum is adapted from the original PARTS program and encompasses a mix of weekly group sessions (120 minutes each) for 20 weeks and individual IFS therapy sessions (minimum 6, and up to 9).

    Behavioral: Program For Alleviating Relationship Trauma and Stress through New Behaviors

  • Active comparator
    DVIT-TAU Arm

    The control group (N=24 anticipated) will follow Treatment As Usual (TAU) for people who use violence in interpersonal and domestic relationships. Currently in WA state, these treatments are a mix of elements from Cognitive Behavioral Therapy (CBT), Duluth Model, and/or Moral Reconation Therapy (MRT). Participants in this group will not be exposed to IFS during TAU to preserve the integrity of the study design. The number of individual counseling sessions during TAU will be tracked, but it can vary based on need in the treatment as usual modalities.

    Behavioral: DVIT Treatment As Usual (TAU)

Interventions

  • BehavioralProgram For Alleviating Relationship Trauma and Stress through New Behaviors

    The experiential protocol includes 15 minutes of themed curriculum and 45 minutes of experiential exercises, e.g., going inside meditation, centering practice, witnessing their own parts, psychodrama, speaking for parts exercises, finding parts in the body, etc. In addition, participants will have 30 minutes to speak in the group about their experience and review the manual focused on new coping strategies and behaviors. We will ask participants to keep a journal to write down observations and parts they notice during the week and ask them to bring the journal and manual we send to them to the group so they can record information they remember after exercises. All participants also will be scheduled to have approximately six to nine standard clinical one-hour sessions with an individual IFS trained counselor (at least Level 1 IFS trained) during their time in the program, with an average of one-two sessions per month (6-9 total individual sessions).

    Also known as: Program For Alleviating Relationship Trauma and Stress - InterPersonal Violence

  • BehavioralDVIT Treatment As Usual (TAU)

    Treatment As Usual (TAU) for people who use violence in interpersonal and domestic relationships. In WA state currently, these treatments are usually a mix of elements from Cognitive Behavioral Therapy (CBT), Duluth Model, and/or Moral Reconation Therapy (MRT). Participants in this group will not be exposed to IFS during TAU, to preserve the integrity of the study design. The number of individual counseling sessions during TAU will be tracked, but it can vary based on need in the treatment as usual modalities.

06

What researchers measure

Primary outcomes

  1. H1.1 - Intervention Feasibility

    70% of participants attend 67% of group sessions Study feasibility: 70% of participants complete of post study assessments For study-protocol feasibility we do not expect differences in the arms but expect each arm to obtain overall 67% or more of participants completing week-20 study assessments (H1.1)

    Time frame: From enrollment to the end of treatment at 20 weeks

Secondary outcomes

  1. H2.1. - Acceptability

    Mean score of 20 on the Client Satisfaction Questionnaire (CSQ-8) general acceptability item A secondary aim is overall acceptability of the intervention as measured by the Client Satisfaction Questionnaire (CSQ-8) (Larsen et al., 1979) where for both arms, we expect a mean score of at least 20 out of a total of 32 (H2.1)

    Time frame: From enrollment to the end of treatment at 20 weeks

  2. H2.2 -- Satisfaction

    Intervention satisfaction, as measured by a satisfaction question (would you recommend a friend) will obtain at least a mean of 7 out of 10 (H2.2) in week 20 for both arms Mean \>7.0 of 10 on willingness to refer a friend on Satisfaction Questionnaire

    Time frame: From enrollment to the end of treatment at 20 weeks

  3. H2.3 -- Conflict Tactics

    Investigate the potential effects of the intervention on the Revised Conflict Tactics Scale (CTS2) (Straus et al., 1996; Chapman \& Gillespie, 2019) and Multidimensional Measure of Emotional Abuse- Restrictive Engulfment (MMEA-RE Subscale) (Murphy \& Hoover, 1999). We hypothesize a risk reduction in physical and psychological violence from self-reports in both arms IFS/DVIT-TAU arm (H2.3). In our pilot (N=12), baseline mean of the psychological aggression subscale was 0.51 (SD=0.17), indicating that some participants had very high aggression scores while others did not. In Week 12, the mean was 0.13 (SD=0.12), suggesting that everyone clustered near zero, with a reduction in variability and suggesting a potential for stabilization in risk. Risk reduction in this case is both improvement and stabilization (decreased or stable scores).

    Time frame: From enrollment to the end of treatment at 20 weeks

  4. H2.4 -- Aggression Experience

    in the pilot PARTS IPV study, we observed declines in the Aggression Experience Sampler (AES) from baseline to week 12. Average baseline scores were 13.97 (SE=0.63) with weekly rates of decline of -0.06 (p-value=0.09), indicating decreases ranging from 0.01 to 0.13 points per week. Based on these pilot findings we hypothesize that the 20-week RCT intervention will produce a weekly decline of -0.04 in AES scores (H2.4)

    Time frame: From enrollment to the end of treatment at 20 weeks

Other outcomes

  1. Exploratory Aim - mechanisms of emotion regulation, decentering, self-critical rumination, and self-compassion

    Exploratory outcomes include effects on mechanisms of emotion regulation, decentering, self-critical rumination, and self-compassion. We hypothesize a greater capacity for decentering (Experiences Questionnaire - Decentering subscale (EQ)), reductions in self-critical rumination, reactivity in interpersonal relationships (OAS2, IRI-SF), as well as an increase in emotion identification and regulation (PAQ-S, Difficulties in Emotion Regulation Scale (DERS)), transcendent experiences (NADA-Bliss subscale), and self-compassion (using Self-Compassion Scale Short Form (SCS-SF)) self report, in IFS PARTS compared to DVIT-TAU at week 12 and 20. Other exploratory aims of the study are to investigate the effects of the intervention on general mental health including posttraumatic stress disorder, depression, anxiety (Achtyes et al., 2015; Guinart et al., 2021), and substance use (Craving Scale, AUDIT-C).

    Time frame: From enrollment to the end of treatment at 20 weeks

07

Study locations

2 sites
08

References and documents

Publications

  • Tobiasz Veltz, L. (2025). Efficacy of an Online, Group-Based Internal Family Systems (IFS) Intervention on PTSD Symptom Clusters. ProQuest Dissertations & Theses.
  • Ally D, Tobiasz-Veltz L, Tu K, Comeau A, Bumpus C, Blot T, Rice FK, Orr B, Soumerai Rea H, Sweezy M, Schuman-Olivier Z. A pilot study of an online group-based Internal Family Systems intervention for comorbid posttraumatic stress disorder and substance use. Front Psychiatry. 2025 Mar 27;16:1544435. doi: 10.3389/fpsyt.2025.1544435. eCollection 2025. PubMed 40212833 ↗
  • Comeau A, Smith LJ, Smith L, Soumerai Rea H, Ward MC, Creedon TB, Sweezy M, Rosenberg LG, Schuman-Olivier Z. Online group-based internal family systems treatment for posttraumatic stress disorder: Feasibility and acceptability of the program for alleviating and resolving trauma and stress. Psychol Trauma. 2024 Dec;16(Suppl 3):S636-S640. doi: 10.1037/tra0001688. Epub 2024 Jun 27. PubMed 38934934 ↗
  • Taft CT, Franz MR, Cole HE, D'Avanzato C, Rothman EF. Examining strength at home for preventing intimate partner violence in civilians. J Fam Psychol. 2021 Sep;35(6):857-862. doi: 10.1037/fam0000732. Epub 2021 Mar 18. PubMed 33734765 ↗
  • Joss D, Comeau A, Chevannes R, Parry G, Rea HS, Barria J, Bumpus C, Rector A, Rajan A, Rosansky J, Rice FK, Ward MC, Tobiasz Veltz L, Ally D, Rosenberg LG, Sweezy M, Lovas D, Schuman-Olivier Z. A randomized controlled trial of an online group-based internal family systems treatment for posttraumatic stress disorder: The Program for Alleviating and Resolving Trauma and Stress (PARTS) study. Psychol Trauma. 2026 Jan 29. doi: 10.1037/tra0002089. Online ahead of print. PubMed 41609644 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 5, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07747766
Lead sponsor
Cambridge Health Alliance
Collaborators
Waterland Counseling Services, Washington State Department of Commerce Office of Crime Victims Advocacy
Responsible party
Zev Schuman Olivier (Director of the Center for Mindfulness and Compassion, Cambridge Health Alliance) — Principal investigator
First posted
Aug 5, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Laure Tobiasz Veltz, ALM, MBA, MS
Contact
ltobiaszveltz@challiance.org
617-806-8735
Zev Schuman-Olivier, MD
principal investigator · Center for Mindfulness & Compassion - Cambridge Health Alliance

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion